GSE169617 azacitidine 1 v 2 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE169617_azacitidine_1_v_2_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE169617_azacitidine_1_v_2_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE169617_azacitidine_1_v_2_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE169617_azacitidine_1_v_2_human_up.

Results found

Linked to

 

Label

Description

 

Gene

G protein signaling modulator 3

Gene

family with sequence similarity 106 member A

Gene

cytoskeleton regulator RNA

Gene

ZNFX1 antisense RNA 1

Gene

mir-100-let-7a-2-mir-125b-1 cluster host gene

Gene

long intergenic non-protein coding RNA, p53 induced transcript

Gene

lung cancer associated transcript 1

Gene

LOXL1 antisense RNA 1

Gene

USP2 antisense RNA 1

Gene

uncharacterized LOC645485

  • Gene

    G protein signaling modulator 3


  • Gene

    family with sequence similarity 106 member A


  • Gene

    cytoskeleton regulator RNA


  • Gene

    ZNFX1 antisense RNA 1


  • Gene

    mir-100-let-7a-2-mir-125b-1 cluster host gene


  • Gene

    long intergenic non-protein coding RNA, p53 induced transcript


  • Gene

    lung cancer associated transcript 1


  • Gene

    LOXL1 antisense RNA 1


  • Gene

    USP2 antisense RNA 1


  • Gene

    uncharacterized LOC645485

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.